Iovance Biotherapeutics (IOVA) Misses Q1 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. CRWD
2. REGN
3. LITE
4. ABBV
5. CL
6. LYB
7. TFII
8. SPY
9. AAPL
10. MRVL

Go back to Iovance Biotherapeutics (IOVA) Misses Q1 EPS by 1c

Iovance Biotherapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update

May 7, 2019 4:02 PM EDT

- First patient dosed in pivotal Cohort 4 in study of lifileucel in advanced melanoma; regulatory submission planned for late 2020 -

- New interim data from melanoma Cohort 2 and cervical cancer studies to be presented in June at the 2019 American Society of Clinical Oncology (ASCO) meeting -

- Company to host conference call at 4:30 p.m. EDT today -

SAN CARLOS, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today reported first... More